Levocabastine is a selective histamine H1 receptor antagonist indicated for the management of seasonal allergic conjunctivitis symptoms. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
- Mechanism
- Curator reviewed
Levocabastine is a potent, selective histamine H1-receptor antagonist. It works by competing with histamine for H1-receptor sites on effector cells. It thereby prevents, but does not reverse, responses mediated by histamine alone. Levocabastine does not block histamine release but, rather, prevents histamine binding and activity. Levocabastine also binds neurotensin 2 receptors and serves as a neurotensin agonist. This can induce some degree of analgesia.
- Primary indication
- As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.Curator reviewed · 2 structured indications
- Formula / weight
- C26H29FN2O2 · 420.528 g/mol (avg)
- First approval
- Canada, 1999 · United States, 2004
- Brand names
Resolves to
ZCGOMHNNNFPNMX-KYTRFIICSA-NSMILESC[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1What you can answer from here — as of September 28, 2026
Which drugs share a target with Levocabastine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account